Fintel reports that on March 13, 2025, Chardan Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Neutral to Buy. Analyst Price Forecast Suggests 234.76% Upside As of March 4 ...

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 ...

CervoMed (NASDAQ:CRVO – Get Free Report) is projected to announce its earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.67) per ...

CervoMed (NASDAQ:CRVO – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports.

In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on CervoMed (CRVO – Research Report). The company’s shares opened today at $2.16. Effectively assess a stock's ...